Advertisement

Author: Staff

Pueblo, Colo.-based Rocky Mountain Eye Center is expected to hold a virtual ribbon-cutting for its new Walsenburg, Colo., office Oct. 13, The Pueblo Chieftain reports.

Takeda has entered into a $1.04 billion licensing agreement with Arrowhead Pharmaceuticals around its phase 2 therapy ARO-AAT, which was designed to treat alpha-1 antitrypsin-associated liver disease.

Advertisement

Revenue in the ASC market is estimated to hit $43 billion in 2021, an increase of 54 percent from 2015, according to a report from Bain & Co. In contrast, the number of procedures performed in ASCs is estimated to…

Advertisement